OBJECTIVE: Emerging evidence has shown the association of aberrant microRNA-375 (miR-375) expression with tumourigenesis in many types of human malignancy. This prospective study characterized the contribution of miR-375 to the initiation and progression of nonsmall cell lung cancer (NSCLC). METHODS: The real-time reverse transcription-polymerase chain reaction was used to examine miR-375 levels prospectively in 96 pairs of samples of NSCLC tissue and adjacent noncancerous tissue (> 2 cm from cancer tissue). The relationship between miR-375 levels and clinico pathological features was also explored. RESULTS: MiR-375 was downregulated in 89% (85/96) of NSCLC samples compared with matched noncancerous tissue samples. Decreased miR-375 correlated significantly with advanced disease stage and lymphatic metastasis. Univariate and multivariate Cox proportional hazard regression analyses revealed that underexpression of miR-375 was an unfavourable prognostic factor for overall survival in NSCLC. CONCLUSIONS: This study suggested that miR-375 is a novel prognostic indicator in NSCLC and might be a potential target for diagnosis and gene therapy.
Introduction
Lung cancer is the most common cause of cancer-associated death worldwide, and nonsmall cell lung cancer (NSCLC) accounts for ~ 80% of all cases of lung cancer. 1 The mortality rate for lung cancer is high because most patients are diagnosed at an advanced clinical stage. Approximately 40% of NSCLC patients who are diagnosed with early stage disease and receive potentially curative treatment relapse within 5 years, whereas the relapse rate increases precipitously in patients diagnosed with advanced disease. 2 Although investigations have identified that multiple genetic changes are involved in the initiation and progression of NSCLC, 3 the precise molecular mechanisms of this disease remain unclear. Biological markers with high sensitivity and specificity for diagnosis, staging and prognosis prediction in NSCLC remain lacking.
MicroRNAs (miRs) are naturally occurring, small (19 to 25 nucleotides in length), single-stranded, noncoding RNAs that mediate gene expression by either Y Li, Q Jiang, N Xia et al.
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cleaving target mRNAs or inhibiting their translation. 4 Studies have revealed a variety of critical biological events that are dependent on faithful miRNA expression, including: cellular development, differentiation, proliferation and death; insulin secretion; haematopoiesis; immune response. 5,6 Furthermore, it is now evident that ~ 50% of miRNAs are located in cancer-associated genomic regions or at fragile sites, 7 and can function as either oncogenes or tumour suppressor genes. 7 Aberrant expression or mutations of miRs have been reported in various types of tumours, including lymphoma, leukaemia, melanoma, cholangiocarcinoma, and breast, gastric, liver, pancreatic, colon or epithelial ovarian cancer. 8 -17 In terms of lung cancer, several miRs are known to be involved in the carcinogenesis and progression of NSCLC, and are correlated with overall survival. 18, 19 One of the earliest members of the miR family to be identified, miR-375, was originally considered an islet-specific miR. Poy et al. 20 reported that overexpression of miR-375 could suppress glucose-induced insulin secretion independently of changes in transmembrane Ca 2+ fluxes or glucose metabolism. Emerging evidence has also shown associations between decreased miR-375 expression and tumourigenesis and progression in melanoma, 21 carcinoma of the head and neck, 22 and pancreatic, 23 oesophageal, 24 gastric, 25 liver 26 or prostate cancer. 27 To our knowledge, there has been little study of the potential role of miR-375 in NSCLC.
The present study compared the levels of miR-375 in paired samples of NSCLC and adjacent noncancerous tissue, and investigated the potential relationship between miR-375 levels and clinicopathological and prognostic outcomes in NSCLC patients
Patients and methods

STUDY POPULATION
In this prospective study, paired samples of cancer tissue and normal adjacent tissue (histologically confirmed, > 2 cm from cancer tissue) were surgically obtained from consecutive patients with NSCLC, who underwent complete resection with curative intent between January 2006 and December 2007 at the Xiangya Hospital, Changsha, China. Other eligibility requirements included a performance status of 0 or 1 based on the Eastern Cooperative Oncology Group (ECOG) criteria 28 and no evidence of distant metastases (confirmed by computed tomography [CT] and magnetic resonance imaging). Patients were excluded if they had a previous or secondary malignancy, and/or had undergone chemotherapy, radiation therapy or immunotherapy. All tissue samples were flash frozen and stored at −80°C in liquid nitrogen immediately after surgery. Tumours were staged according to the 6 th edition of the International Union Against Cancer tumour-node-metastasis (TNM) staging system. 29 The Medical Ethics Committee of Xiangya Hospital approved this study and all patients provided written informed consent prior to undergoing surgery.
RNA EXTRACTION AND RT-PCR ANALYSIS OF miR-375
Total RNA from 20 -50 mg of NSCLC tissue and corresponding adjacent normal tissue was isolated using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA quality and quantity were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Expression of miR-375 was assessed by quantitative real-time reverse transcriptionpolymerase chain reaction (RT-PCR); the small nuclear RNA U6 was used as an Y Li, Q Jiang, N Xia et al.
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internal control. cDNA specific to miR-375 and RNA U6 were synthesized from total RNA using gene-specific primers (as previously described) 20, 24 and the TaqMan ® microRNA assay (Applied Biosystems, Foster City, CA, USA). RT reactions contained 10 ng total RNA, 50 nmol/l stem-loop RT primer, 1x RT buffer, 0.25 mmol/l each deoxynucleotide triphosphate (dNTP), 3.33 units/µl MultiScribe™ reverse transcriptase and 0.25 units/µl RNase inhibitor in a total volume of 7.5 µl (all from Applied Biosystems). Reactions were incubated in a 96-well plate for 30 min at 16°C, followed by 30 min at 42°C and 5 min at 85°C, then held at 4°C for 15 min.
Real-time PCR was performed using the Applied Biosystems ® 7500 real-time PCR System (Applied Biosystems). Reactions were carried out in 96-well plates in a total volume of 10 µl (0.67 µl RT products, 1 × TaqMan ® universal PCR master mix, 1 µl TaqMan ® microRNA assay primer and probe mix). The cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 45 cycles of denaturation at 95°C for 15 s, annealing at 55°C for 30 s and elongation at 70°C for 30 s, followed by a final elongation step at 60°C for 10 min. All samples were processed in triplicate. The threshold cycle (CT) was defined as the cycle number at which the fluorescence passed the fixed threshold, and the relative amount of miR-375 to U6 was calculated using the equation 2 -∆CT , where ∆CT = (CT miR-375 − CT U6 ). 30
FOLLOW-UP
Follow-up was performed every 3 months during the first 2 years after resection and every 6 months thereafter. Each follow-up consisted of a physical examination, complete blood count, liver function tests, assessment of serum tumour markers, chest X-ray and CT scan.
STATISTICAL ANALYSES
Statistical analyses were performed with SPSS ® statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Values are expressed as mean ± SD. Differences in miR-375 levels between groups were compared using Student's t-test. Survival time was calculated from the date of surgery to death or last follow-up. The association between levels of miR-375 and overall survival was analysed by Spearman's correlation coefficient. The joint effect of covariables was examined using the Cox proportional hazard regression model. All tests were two-tailed and a P-value < 0.05 was considered to be statistically significant.
Results
In total, 96 patients (70 male, 26 female), median age 61 (range 37 -75) years were included in the study. Paired samples of NSCLC and adjacent noncancerous tissue were surgically obtained from each patient.
Levels of miR-375 were decreased in 89% (85/96) of lung cancer tissue samples compared with the matched adjacent noncancerous tissue samples. The mean ± SD ∆CT value of miR-375 in NSCLC tissue was 12.13 ± 1.62 compared with 8.47 ± 0.86 in adjacent noncancerous tissue (P < 0.001).
Patient characteristics with respect to decreased miR-375 expression are shown in Table 1 . The primary tumour size was ≤ 3.0 cm in 34% (33/96) of patients; 58% (56/96) had positive lymph node tumours. Decreased miR-375 was significantly correlated with advanced disease stage (P = 0.016) according to the TNM staging system, 29 Spearman's correlation coefficient analysis showed significant correlation between miR-375 expression (∆CT) and survival time (ρ = −0.745, P < 0.001; Fig. 1 ). Table 2 presents results of univariate and multivariate Cox proportional hazard regression analyses, investigating the relationships between miR-375 levels and NSCLC characteristics and prognosis. Univariate Cox proportional hazard regression analysis revealed that miR-375 expression levels (hazard ratio [HR] = 2.65; P = 0.012), TNM stage 29 (HR = 3.47; P = 0.006) and lymphatic metastasis (HR = 2.29; P = 0.021) were predictive factors for prognosis, in NSCLC patients. Multivariate regression analysis confirmed that downregulation of miR-375 (HR = 3.29; P = 0.018) and advanced TNM stage 29 (HR = 3.55; P = 0.010) were independently unfavourable prognostic factors for overall survival.
Discussion
There is growing evidence that miRNAs can function as oncogenes or tumour suppressors by repressing the expression of important cancer-related genes. 31 Misexpression, mutation and altered mature miRNA processing are implicated in tumourigenesis and progression in many types of cancer. 32 For lung cancer, several miRNAs have demonstrated potential diagnostic and prognostic utility. It has been shown, for 
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example, that the miR-17-92 cluster is markedly overexpressed in lung cancer, and that the introduction of these miRs could enhance lung cancer cell growth. 33 In another study, decreased expression of the miR-let-7 family in lung cancer was associated with shortened postoperative survival rates. 19 Additionally, using real-time RT-PCR, a five-miRNA signature was shown to predict treatment outcome in NSCLC patients. 34 The present study was the first to demonstrate that miR-375 is downregulated in cancerous tissue, and that low miR-375 levels are closely correlated with advanced tumour stage, lymphatic metastasis and shorter overall survival. These findings are in agreement with previous studies.
Misexpression of miR-375 is associated with human melanoma cell proliferation, invasion, and changes in cell motility and appearance. 21 In addition, miR-375 was significantly downregulated in liver cancer cell lines and hepatocellular carcinoma tissues, and overexpression of miR-375 in liver cancer cells was associated with decreased cell proliferation, clonogenicity, invasion and migration. 26 In another study, miR-375 was identified as one of the most pronounced markers for tumour progression in patients with prostate cancer. 27 The findings from these studies suggest that miR-375 may play an important role, not only in tumour initiation but also in the development and progression of many other malignancies. The mechanism by which miR-375 expression affects tumour behaviour has been described in few published reports. MiR-375 may function as a tumour suppressor to inhibit proliferation of gastric cancer cells by targeting the tyrosine kinase Janus kinase 2 (JAK2). 25 Furthermore, miR-375 could bind directly to the 3′untranslated region of AEG-1, an important oncogene involved in multiple aspects of cancer development and progression, 35, 36 and inhibit its expression. 26 In human pancreatic adenocarcinoma cells, a potential link exists between miR-375 expression and levels of both caveolin-1 and insulin-like growth factor binding protein-5 mRNA, 23 which are proteins associated with the aggressiveness of pancreatic cancer. 37, 38 In addition, miR-375 is a negative regulator of 3-phosphoinositide-dependent protein kinase-1 (PDK1) in oesophageal cancer, and downregulation of miR-375 plays an important role in tumourigenesis, partially through activation of the PDK1/Akt pathway. 24 Each miRNA can, however, target over 100 transcripts directly or indirectly. 39 Conversely, several miRNAs can converge on a single transcript target. 40 Thus, the potential regulatory circuitry afforded by miR-375 may be enormous, and identification of the complex molecular network involved in its function remains an important subject for future investigation.
In conclusion, miR-375 was downregulated in NSCLC, and this decrease was associated with advanced tumour stage and shortened overall survival time. These results may encourage the development of effective gene therapies that target miR-375 (or its targets) for the treatment of NSCLC.
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